HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer

HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer

While the results thus far demonstrate the clinical benefit of trastuzumab in breast cancer (BC), some patients do not respond to this drug. HER2 mRNA, alone or combined with other genes/biomarkers, has been proven to be a powerful predictive marker in several studies. Here, we provide evidence of t...

Full description

Bibliographic Details
Main Authors: Tiziana Triulzi, Viola Regondi, Elisabetta Venturelli, Patrizia Gasparini, Cristina Ghirelli, Jessica Groppelli, Martina Di Modica, Francesca Bianchi, Loris De Cecco, Lucia Sfondrini, Elda Tagliabue
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cancers
Subjects:
breast neoplasms
trastuzumab
mRNA
receptors
estrogen
estradiol
Online Access:https://www.mdpi.com/2072-6694/14/22/5650

Internet

https://www.mdpi.com/2072-6694/14/22/5650

Similar Items